Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma

BACKGROUND: The results of phase 1 and phase 2 studies suggest that nivolumab (a PD-1 checkpoint inhibitor) and ipilimumab (a CTLA-4 checkpoint inhibitor) have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab combined with i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Larkin, James, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean Jacques, Cowey, C. Lance, Lao, Christopher D., Schadendorf, Dirk, Dummer, Reinhard, Smylie, Michael, Rutkowski, Piotr, Ferrucci, Pier Francesco, Hill, Andrew, Wagstaff, John, Carlino, Matteo S., Haanen, John B., Maio, Michele, Marquez-Rodas, Ivan, McArthur, Grant A., Ascierto, Paolo A., Long, Georgina V., Callahan, Margaret K., Postow, Michael A., Grossmann, Kenneth, Sznol, Mario, Dreno, Brigitte, Bastholt, Lars, Yang, Arvin, Rollin, Linda M., Horak, Christine, Hodi, F. Stephen, Wolchok, Jedd D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5698905/
https://ncbi.nlm.nih.gov/pubmed/26027431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1504030
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados